Document:

EX-10.6

 EXHIBIT 10.6 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF
PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAVE BEEN REDACTED. 
 NOTE ABOUT TRANSLATION: 

This document is an English translation of a document in Italian language. In preparing this document, an attempt has been made to translate as literally as
possible without jeopardizing the overall continuity of the text. Inevitably, however, differences may occur in translation and if they do, the Italian text will govern by law. In this translation, Italian legal concepts are expressed in English
terms and not in their original Italian terms. The concepts concerned may not be identical to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. 

UNOFFICIAL ENGLISH TRANSLATION OF THE RESTRICTED STOCK GRANT PLAN STEVANATO GROUP S.P.A. 2021-2027 REGULATION 

Premises 
  

	(a)	 Stevanato Group S.p.A., with registered offices in Piombino Dese (PD), via Molinella 17, registration number at
the Companies’ Register of Padova, tax and VAT code no. 01487430280, share capital Euro 20.002.000,00 fully paid in (hereinafter referred to as “SG” or the “Company”), with the resolution adopted by the
Shareholders’ Meeting of March 4 2021, decided to adopt an incentive plan for the benefit of some individuals who will be identified by SG’s administrative body, (hereinafter referred to as “Beneficiaries” and
analytically as defined below) approving at the same time this regulation (hereinafter also the “Regulation”) governing the Stock Grant Plan Stevanato Group S.p.A. 2021-2027 (hereinafter also the “Stock Grant
Plan”), and assuming the commitment to ensure that the Beneficiaries may become owner of SG Shares at the terms and conditions set forth under this Regulation; 

 

	(b)	 through the implementation of the Stock Grant Plan, SG intends to involve the Beneficiaries in the economic and
strategic development of the Company and of the entire SG Group (as defined below), aligning their interests with those of Company’s shareholders and stakeholders. 

All this being said, the Stock Grant Plan shall be governed by this Regulation: 
  

	1.	 DEFINITIONS 

For the purposes of this Regulation the terms indicated below shall have the meaning ascribed to them in this article 1: 

 

	1.1	 “Agreement” means the agreement between SG and each of the Beneficiaries containing the the
constraints governed by Articles. 6, 9 and 10 of this Regulation to which the Shares and Shares Additionally Assigned, are subject and to which the Beneficiaries undertake to comply with; 

	1.2	 “Shares” collectively (and “Share” individually) means the shares representing the share
capital of SG subject to a free assignment to the Beneficiaries in each Vesting Period (as defined below); 

  

	1.3	 “Shares Additionally Assigned” means shares representing the share capital of SG which will be
assigned free of charge in case of the occurrence of the conditions required for the Additional Assignment Free of Charge (as defined below); 

  

	1.4	 “Beneficiary” (collectively “Beneficiaries”) means each employee of SG and/or of a company
of the SG Group, or each self-employed worker working for SG and/or a company of the SG Group, identified by the SG’s administrative body as individual playing a strategic role in SG and/or in a company of the SG Group and to whom will be sent
the Grant Letter, and in case of the occurrence of the conditions required, the Additional Grant Letter (as defined below); 

  

	1.5	 “BP SGP” or “Business Plan SGP” means the consolidated organic plan containing the
economic and financial basic parameters of the Stock Grant Plan in the period coverd by the plan, and in particular the Revenue Targets and the Ebitda Targets. Such plan, once formally approved by the competent bodies, will be attached to this
Regulation under Exhibit “A”; 

  

	1.6	 “Assignment Date of the Shares” means the date on which the SG’s administrative body will send
to each Beneficiary the Grant Letter; 

  

	1.7	 “Assignment Date of the Shares Additionally Assigned” means the date on which the SG’s
administrative body will send to each Beneficiary the Additional Grant Letter; 

  

	1.8	 “Prohibition to Sell” is the temporary prohibition, pursuant to art. 9 of this Regulation, applied to
the Beneficiaries, to transfer, with a deed between living persons and/or as a result of death, the Shares and the Shares Additionally Assigned to other entity than SG; 

 

	1.9	 “Selling Commitment” is the unconditional and irrevocable commitment undertaken the Beneficiaries to
sell to SG, if SG expresses the will to buy through the Call Option 1 exercise and or through the Call Option 2 exercise, the Shares and the Shares Additionally assigned to the Beneficiaries in each Vesting Period, pursuant to the rules stated in
art. 10 of this Regulation; 

  

	1.10	 “Ebitda” means Earnings Before Interest, Taxes, Depreciation and Amortization of SG determined on the
basis of SG’s consolidated financial statements as of December 31 of each year pursuant to the provisions under Attachment E; 

  

	1.11	 “Final Ebitda” indicates the amount calculated on the basis of SG’s consolidated financial
statement, prepared in accordance with the IAS/IFRS accounting principles, presented to SG’s Shareholders’ Meeting upon the approval of financial statements; 

 

	1.12	 “Final Cumulative Ebitda” means the sum of the Final Ebitda of each year of the two-year period corresponding to each Vesting period; 

  

	1.13	 “Trustee” means the trustee company designated by the Company or the entity which will be entitled to
ensure the proper fulfilment of the obligations indicated in this Regulation; 

  

	1.14	 “Business Day” means any day on which the credit institutions are open to the public in Italy;

  

	1.15	 “SG Group” means SG together with the companies directly or indirectly controlled by SG pursuant to
Article 2359 no. 1) and 2) of Italian Civil Code; 

	1.16	 “Grant Letter” means the letter prepared in the form set out in Exhibit “B” attached to
this Regulation and sent to the Beneficiary within 180 days from the beginning of each Vesting period, through which the Company communicates to the Beneficiary the number of Shares assigned free of charge, the restrictions related to such Shares,
the criteria used for the assignment of the Shares Additionally Assigned, as well as the main contents of this Regulation which will be attached to the same Grant Letter; 

 

	1.17	 “Revenue Target” (in the plural “Revenue Targets”) means the sum of the Final Revenues
identified in the BP SGP on the basis of the yearly consolidated financial statements and related to each two-year period of each Vesting period, the achievement of which, in terms of Final Cumulative
Revenues, is verified by SG’s administrative body at the end of each individual Vesting period; 

  

	1.18	 “Ebitda Target” (in the plural “Ebitda Targets”) means the sum of the Ebitda identified in
the BP SGP on the basis of the yearly consolidated financial statements and related to each two-year period of each Vesting period, the achievement of which, in terms of Final Cumulative Ebitda, is verified by
SG’s administrative body at the end of each individual Vesting period;; 

  

	1.19	 “Call Option 1” and “Call Option 2” is the power granted by the Beneficiaries to SG to
request to the Beneficiaries the sale to SG of all the or a portion of the Shares, (Call Option 1), and all the or a portion of the Shares and of the Shares Additionally Assigned, (Call Option 2), assigned to them free of charge in each Vesting
Period pursuant to the art. 10 of this Regulation; 

  

	1.20	 “Vesting Period” means each of the three two-year period
between, respectively, January 1 2021 and December 31 2022 (First Vesting Period), January 1 2023 and December 31 2024 (Second Vesting Period), January 1 2025 and December 31 2026 (Third Vesting Period), at the
beginning of which SG will assign free of charge to the Beneficiaries the property of the Shares which will be subject to the Prohibition to Sell (as defined by art. 1.8) and to the Selling Commitment (as defined by art. 1.9); 

 

	1.21	 “Lock-up Period” means the
one-year period, following each one Vesting Period, after which the ownership of the Shares assigned in such Vesting Period and of the Shares Additionally Assigned related to such Vesting Period will be freely
transferable from the Beneficiaries to entity or person other than SG. Until the end of the Lock-up Period as determined above the Beneficiary shall maintain the Shares free from any possible option and pre-emption right or any other restriction or limitation, either contractual and/or non-contractual including, but not limited to, absence of any encumbrance such as pledge,
or other interests as warranty (“interessi in garanzia”) due or granted to third parties, or foreclosure, preventive seizure or other type of charge of any other nature, except for those arising from the by-laws of SG and/or by this Regulation and/or by explicit and particular authorisations decided by the administrative body of SG; 

 

	1.22	 “Sale Price” of the Shares means the price determined pursuant to article 11 of this Regulation at
which the Shares and/or the Shares Additionally Assigned will be sold in all cases in which, after verification that the conditions are met, SG will exercise the Call Option 1 and/or the Call Option 2 pursuant to this Regulation and/or to the
Agreement; 

  

	1.23	 “Accounting Principles” means the international accounting principles IAS/IFRS prepared by the IASB
(International Accounting Standards Board); 

	1.24	 “Regulation” means this Regulation of the Stock Grant Plan Stevanato Group S.p.A. 2021-2027 approved
with the resolution of the Shareholders’ Meeting of SG on March 4 2021; 

  

	1.25	 “Revenues” indicates the item Revenues of the scheme of the profit and loss account of SG’s
consolidated financial statements prepared in accordance with the IAS/IFRS accounting principles; 

  

	1.26	 “Final Revenues” means the item Revenues of the scheme of the profit and loss account of SG’s
consolidated financial statements prepared in accordance with the IAS/IFRS accounting principles, presented to SG’s Shareholders’ Meeting upon the approval of financial statements; 

 

	1.27	 “Final Cumulative Revenues” means the sum of the Final Revenues of each of each year of the two-year period corresponding to each Vesting Period; 

  

	1.28	 “Written Request 1” indicates the letter sent by SG to the Beneficiaries containing the will to
exercise the Call Option 1 

  

	1.29	 “Written Request 2” indicates the letter sent by SG to the Beneficiaries containing the will to
exercise the Call Option 2; 

  

	1.30	 “Stock Grant Plan” means the Stock Grant Plan Stevanato Group S.p.A. 2021-2027 approved with the
resolution of the Shareholders’ Meeting of SG on March 4 2021, governed by this Regulation; 

  

	1.31	 “Additional Assignment Free of Charge” means the additional assignment free of charge by SG to the
Beneficiaries related to each Vesting Period (the Shares Additionally Assigned) to put in place if at the end of this Vesting Period the Final Cumulative Ebitda will be at least 1% (one percent) greater than the Ebitda Target related to the same
Vesting Period; 

  

	1.32	 “Additional Grant Letter” means formset out in Exhibit “C” attached to this Regulation and
sent to the Beneficiary within 120 days from the end of each Vesting Period, through which the Company communicates to the Beneficiary the number of Shares Additionally Assigned related to the above mentioned Vesting Period and the restrictions
related to such Shares Additionally Assigned. 

  

	2.	 SUBJECT OF THE REGULATION 

 

	2.1	 In compliance with the resolution taken by the Shareholders’ Meeting of SG adopted on March 4 2021
and with this Regulation, at the beginning of each Vesting Period, SG will grant free of charge to the Beneficiaries a certain number of Shares. The Shares assigned will be subject to: 

 

	 	a)	 the Prohibition to Sell governed by the art. 9.1 and 9.2 of this Regulation; 

 

	 	b)	 the Selling Commitment governed by the art. 10 of this Regulation. 

 

	2.2	 The number of Shares that SG will grant free of charge at the beginning of each Vesting Period is that
indicated in the Grant Letter sent to each Beneficiary in accordance with the terms provided by art. 14 of this Regulation. 

  

	2.3	 If at the end of each Vesting Period the Final Cumulative Ebitda will be at least 1% (one percent) greater than
the Ebitda Target related to the same Vesting Period, SG will assign free 

	 	
of charge to the Beneficiaries with reference of the above mentioned Vesting Period a certain number of Shares Additionally Assigned. In particular it is provided that the Shares Additionally
Assigned (SAA) should be determined according to the following formula: 

 SAA = SA x (n*i) 

Where ‘SA’ are the Share assigned in the Vesting Period just concluded and ‘i’ is the increasing percentage of the Final
Cumulative Ebitda compared with the Ebitda Target and ‘n’ will be a certain number determined by the administrative body of SG at the beginning of each Vesting Period. 

The Shares Additionally Assigned will be subject to the Prohibition to Sell pursuant to the art. 9.3 and 9.4 of this Regulation. 

 

	2.4	 The number of the Shares Additional Assigned that SG will assign free of charge after the end of each Vesting
Period during which the condition provided for the Additional Assignment Free of Charge are met, as determined with the above mentioned formula, will be that indicated in the Additional Grant Letter sent to the Beneficiary with the provisions
pursuant to the art. 14 of this Regulation. 

  

	3.	 STOCK GRANT PLAN MANAGEMENT 

 

	3.1	 The corporate body in charge of managing the Stock Grant Plan is the administrative body of SG, which will act
in compliance with the resolution of the Shareholders’ Meeting of SG adopted on March 4 2021 and with this Regulation; 

  

	3.2	 The administrative body of SG has all the powers of operational management of the Stock Grant Plan, including,
but not limited to, the power to identify the Beneficiaries to whom the Shares and the Shares Additionally Assigned are assigned among the employees and the self-employed playing a strategic role in SG Group and to determine the number of Shares and
of Shares Additionally Assigned to be granted to each of said Beneficiaries in compliance with the terms and conditions set forth under this Regulation. 

  

	3.3	 All the communications to be made by the Beneficiary related to and/or pursuant to the Stock Grant Plan shall
be addressed to the administrative body of SG. 

  

	3.4	 If required or appropriate with respect to extraordinary operations events or particular circumstances
concerning the Company or SG Group, the administrative body and/or the shareholders’ meeting of SG will be entitled to revoke the Stock Grant Plan or to suspend its performance. In these cases, the Beneficiaries will receive a 30-day prior notice with respect to the day on which the revocation or the suspension will be effective. In case of such revocation or suspension of the Stock Grant Plan, the Company will grant each Beneficiary with
a different incentive, unless after the completion of the extraordinary operation, event or particular circumstance as above mentioned, the administrative body and/or the shareholders’ meeting of SG approves the resolutions necessary for the
issuance of a new incentive plan in case of revocation of the Stock Grant Plan, or for the reactivation of this latter in case of suspension of the same, in both cases in order to ensure that the treatment reserved to the Beneficiaries in case of
granting of the different incentive or pursuant to the new incentive plan or the Stock Grant Plan reactivated is substantially equal to the one that would have been reserved to each Beneficiary on the basis of the circumstances existing before the
revocation or the suspension of Stock Grant Plan. 

	4.	 IMPLEMENTATION OF THE PLAN 

 

	4.1	 The Beneficiaries will not have any right with respect to the Stock Grant Plan unless starting from the date of
receipt of, and within the limits provided for by the Grant Letter. 

  

	4.2	 The Grant Letter will have to be sent to the Beneficiaries within 180 days from the beginning date of each
Vesting Period. The Additional Grant Letter will have to be sent to the Beneficiaries within 120 from the end date of each Vesting Period in which the conditions provided for the Additional Assignment Free of Charge are met. 

 

	4.3	 The Grant Letter will include the indication of: 

 

	 	a)	 the total number of Shares assigned free of charge to the Beneficiary related to each Vesting Period and the
mechanism used to determine the Shares Additionally Assigned which may be assigned free of charge; 

  

	 	b)	 the Revenue Targets and/or the Ebitda Targets which, if not achieved at the end of the Vesting Period, entitle
SG to exercise the Call Option 1 of the Shares, and the achievement of which entitle the Beneficiaries to receive the Additional Assignment Free of Charge; 

  

	 	c)	 the other events which, if occurred, entitle SG to exercise the Call Option 1 related to the Shares assigned
free of charge in each Vesting Period; 

  

	 	d)	 the date when and the place where all the relevant formalities, necessary to transfer free of charge to the
Beneficiary the ownership of the Shares and to execute the fiduciary mandate of such Shares pursuant to art. 6.1 and 6.2 of this Regulation; 

  

	 	e)	 the possibility for the Beneficiary to request to SG the grant of an interest-bearing loan in order to the pay
the tax and social security charges deriving from the free of charge assignment of the Shares to the Beneficiary. 

  

	4.4	 The Additional Grant Letter will include the indication of: 

 

	 	a)	 the total number of Shares Additionally Assigned free of charge to the Beneficiary related to the Vesting
Period in which the conditions provided for the Additional Assignment Free of Charge are met; 

  

	 	b)	 the date when and the place where all the relevant formalities, necessary to transfer free of charge to the
Beneficiary the ownership of the Shares Additionally Assigned and the execution of the fiduciary mandate of such Shares Additionally Assigned pursuant to art. 6.1 and 6.2 of this Regulation; 

 

	 	c)	 the possibility for the Beneficiary to request to SG the grant of an interest-bearing loan in order to the pay
the tax and social security charges deriving from the free of charge assignment of the Shares Additionally Assigned. 

	4.5	 The transfer free of charge of the Shares and of the Shares Additionally Assigned to the Beneficiary related to
each Vesting Period will be carried out after the signing of the Agreement by the Beneficiary pursuant the art. 10.1 of this Regulation as detailed in the Exhibit “D” attached to this Regulation. Failure by the Beneficiary to enter into
such an Agreement shall, with retroactive effect, result in the cancellation of the assignment of the Shares communicated with the Grant and of the Shares Additionally Assigned communicated with the Additional Grant Letter. 

 

	5.	 REQUIREMENTS AND CRITERIA FOR THE GRANTING OF THE SHARES 

 

	5.1	 The granting of the Shares to the Beneficiaries is deemed subject to the holding, by each of them, on the
Assignment Date of the Shares, of the following requirements: 

  

	 	(a)	 attendance at work under an employment contract of indefinite duration for, or the permanence under an
independent work relationship in favour of, a company of the SG Group; 

  

	 	(b)	 the notice period for the resignation, lawful dismissal or termination of the self-employment activities is not
running. 

 The requirement under (b) above will be deemed as fulfilled if, despite the running of the notice period for
resignation, lawful dismissal or termination of the self-employment activities, it is provided, after the above-said period and without interruptions, the establishment of a new work relationship, at any title, or the renewal of the former one, with
SG or with companies of SG Group. 
  

	6.	 TRUSTEE MANDATE 

 

	6.1	 The Shares assigned free of charge to the Beneficiaries in each Vesting period and the Shares Additional
Assigned related to this Vesting Period shall be registered to a Trustee company, identified by SG, or, in case of dematerialization of the Shares, deposited into an account/securities portfolio registered to the Trustee. The Beneficiary will have
to grant to the Trustee a fiduciary mandate which will be irrevocable since it will be granted also in the Company’s interest, to manage the Shares during each Vesting Period and the Shares Additionally Assigned related to the same Vesting
Period in its own name and on behalf of the Beneficiary, pursuant to art. 1723 al. 2 of the Italian Civil Code, as well as to monitor the proper compliance with the present Regulation and the agreements to be executed between the Beneficiary and the
Company in accordance with the Regulation. 

  

	6.2	 The Trustee Mandate under art. 6.1 related to the assigned Shares in each Vesting Period will be valid:

  

	 	a)	 until the end of the Lock-up Period subsequent to the Vesting Period
during which the Shares have been assigned, if within that deadline the Beneficiary has not received the Written Request, set forth under art. 10.2, containing the will express by SG to exercise the Call Option 1 related to those Shares;

	 	b)	 until the date of the transfer of the property of the Shares to SG deriving from the timely exercise of the
Call Option 1 of those Shares by SG, in any other case. 

  

	6.3	 The Trustee Mandate governed by the art. 6.1 related to the Share Additionally Assigned to the Beneficiaries
with reference to each Vesting Period in which the conditions provided for the Additional Assignment Free of Charge will be valid until the end of the Lock-up Period subsequent to this Vesting Period;

  

	6.4	 The Restrictions related to the Shares and to the Shares Additionally Assigned in accordance with art. 6.1, 6.2
and 6.3 of this Regulation will be included in the Agreement as defined at the art. 10 of this Regulation. 

  

	7.	 RIGHTS OF SG 

  

	7.1	 It is expressly understood that what is set forth under the Stock Grant Plan and the rights that may be granted
to the Beneficiary in accordance to the same, are in no way capable to modify the terms and conditions of the work relationship between the Beneficiary and the relevant company of the SG Group. In particular, without prejudice to the generality of
the foregoing, the company of the SG Group will be fully entitled to terminate the work relationship with the Beneficiary in accordance to law and the relevant agreement regulating such work relationship. 

 

	8.	 BENEFICIARIES’ RIGHTS 

The Beneficiaries will not lose their rights deriving from this Regulation if, after the sending the Grant Letter and the Additional Grant
Letter in accordance with the art. 4 of this Regulation, should extraordinary transactions, special events or circumstances occur, such as to entail the application of art. 3.4 of the Regulation. 

 

	9.	 PROHIBITION TO SELL 

 

	9.1	 Without prejudice to the following paragraphs 9.2, the Shares assigned free of charge to each Beneficiary
through the assignment carried out during each Vesting Period, may not be transferred, by the Beneficiary, or by the heirs in case of death of the Beneficiary, to any person or entity other than SG until the end of the
Lock-up Period, indicated in the Grant Letter, subsequent to the Vesting Period when those Shares were assigned, and in any case until the time of transfer to SG of the Shares as a result of the Call Option 1
timely exercised by SG pursuant to this Regulation. Until the end of the Lock-up Period as determined above, the Beneficiary shall maintain the Shares free from any possible option and pre-emption right or any other restriction or limitation, either contractual and/or non-contractual including, but not limited to, absence of any encumbrance such as pledge,
or other interests as warranty (“interessi in garanzia”) due or granted to third parties, or foreclosure, preventive seizure or other type of charge of any other nature, except for those arising from the by-laws of SG and/or by this Regulation and/or by explicit and particular authorisations decided by the administrative body of SG. 

	9.2	 SG’s administrative body may decide to reduce the Lock-up Period
or to not apply any Lock-up Period in relation to such Beneficiary or to provide a partial restriction with reference to the Share transfer for this Beneficiary, in case this should be needed on the basis of
specific circumstances – to be evaluated at the discretion of the administrative body – in order to preserve the incentive purpose of the Stock Grant Plan. 

 

	9.3	 Without prejudice to the following paragraphs 9.4, the Shares Additionally Assigned to the Beneficiary related
to each Vesting Period in which the conditions provided for the Additional Assignment Free of Charge are met may not be transferred, by the Beneficiary, or by the heirs in case of death of the Beneficiary, to any person or entity other than SG until
the end of the Lock-up Period, indicated in the Additional Grant Letter subsequent to this Vesting Period when those Shares were assigned. Until the end of the Lock-up
Period as determined above, the Beneficiary shall maintain the Shares Additionally Assigned free from any possible option and pre-emption right or any other restriction or limitation, either contractual and/or
non-contractual including, but not limited to, absence of any encumbrance such as pledge, or other interests as warranty (“interessi in garanzia”) due or granted to third parties, or
foreclosure, preventive seizure or other type of charge of any other nature, except for those arising from the by-laws of SG and/or by this Regulation and/or by explicit and particular authorisations decided
by the administrative body of SG. 

  

	9.4	 SG’s administrative body may decide to reduce the Lock-up Period
or to not apply any Lock-up Period in relation to such Beneficiary or to provide a partial restriction with reference to the Share Additionally Assigned for this Beneficiary, in case this should be needed on
the basis of specific circumstances – to be evaluated at the discretion of the administrative body – in order to preserve the incentive purpose of the Stock Grant Plan. 

 

	9.5	 The Restrictions related to the Shares and to the Shares Additionally Assigned in accordance with art. 9.1 and
9.3 of this Regulation will be included in the Agreement as defined at the art. 10 of this Regulation. 

  

	10.	 SELLING COMMITMENT 

 

	10.1	 By signing the Agreement with SG, each Beneficiary undertakes unconditionally and irrevocably to sell to SG, at
the sale price as determined under the art. 11 of this Regulation (hereinafter the “Sale Price”), the total number of Shares or a portion of Shares assigned to the Beneficiary in each Vesting Period if SG expresses in writing the
will to exercise the Call Option 1, granted to SG through the subscription of the above mentioned Agreement, the exercise of which depends, with a suspensive effect, if at least one of the following events occurs: 

 

	 	a)	 after the date when the Beneficiary becomes the owner of the Shares assigned free of charge and within the end
of each Vesting Period, (i) the employment relationship of indefinite duration with a company of SG group terminates for death, resignation, lawful dismissal or for a justified subjective reason, or the self-employment in favour of a company of
SG group terminates, (ii) the notice period for the resignations, lawful dismissal or for a justified subjective reason or termination of the self-employed relationship is running, unless after the above-said period and without interruptions,
the establishment of a new work relationship, at any title, or the renewal of the former one, with SG or with companies of SG Group has occurred. Any of the above mentioned 

	 	
events allows SG to exercise the Call Option 1 of the Shares owned by the Beneficiary, or by the heirs in case of death of the Beneficiary, as a result of the assignment relating to that Vesting
Period. For the purpose of evaluating the occurrence of the above mentioned circumstances the following rules apply: 

  

	 	i.	 the employment relationship of indefinite duration with, or the self-employment in favour of, a company of SG
group shall be deemed as terminate at the date of termination of the aforesaid relationship becomes effective; 

  

	 	ii.	 the notice period will be effective on the date of receipt by the Company of the resignation letter or by the
addressee of the layoff communication in case of lawful dismissal or for a justified subjective reason or by the communication of termination of the self-employed relationship; 

 

	 	iii.	 the death of the Beneficiary that occurred prior to the end of the Vesting Period in which the Shares were
assigned shall be regarded as termination of the employment relationship which is relevant for the exercise by SG’s of the Call Option 1; 

  

	 	b)	 within the end of this Vesting Period the Revenues Targets and/or Ebitda Targets have not been fully or
partially achieved, on the basis of SG’s consolidated financial statements as of December 31 of each year as part of the Stock Grant Plan period, presented to SG’s Shareholders’ Meeting upon the approval of financial statements.
Subsequently the Revenue Targets and/or Ebitda Targets verification, the Call Option 1 may be exercised by SG for: 

  

	 	i.	 the 15% of the Shares assigned free of charge in the specific Vesting Period, if the Final Cumulative Revenues
reached at least 95%, but not exceed 100%, of the Revenues Target under the BP SGP relating to the two-year period of such Vesting Period; 

 

	 	ii.	 the 30% of the Shares assigned free of charge in the specific Vesting Period, if the Final Cumulative Revenues
reached at least 85%, but not exceed 95%, of the Revenues Target under the BP SGP relating to the two-year period of such Vesting Period; 

 

	 	iii.	 the 100% of the Shares assigned free of charge in the specific Vesting Period, if the Final Cumulative Revenues
reached at least 85% of the Revenues Target under the BP SGP relating to the two-year period of such Vesting Period; 

  

	 	iv.	 the 10% of the Shares assigned free of charge in the specific Vesting Period, if the Final Cumulative Revenues
are equal or exceed 100% of the Revenues Target under the BP SGP relating to the two-year period of such Vesting Period but the Final Cumulative Ebitda is lower than 90% of the Ebitda Targets under the BP SGP
relating to the two-year period of tsuch Vesting Period; 

  

	 	v.	 the percentages above indicated under points (i) and (ii), related to quota subject to the Call Option 1
exercised by SG, will be increased 

	 	
respectively to 30% and to 60% in case the Final Cumulative Ebitda is lower than 90% of the Ebitda Target under the BP SGP relating to the two-year period
of such Vesting Period; 

 If, with respect to the application of the percentages above indicated, it results the calculated number of the
Shares subject to the Call Option 1 expressed in decimals, this number will be rounded up to units, if the decimals is equal or exceed fifty cents, or down to units, if the decimals lower than fifty cents. 

 

	10.2	 The Call Option 1 will be exercised by SG by sending to the Beneficiary, to the address and in the manner
specified at the art. 14, a written communication containing the will to exercise the Call Option 1 and the indication of the conditions for applying the Call Option 1, the number of Shares object of the Call Option 1, the Sale Price and as well as
of the date when and the place where all the relevant formalities related to the transfer of the ownership of the above mentioned Shares will be performed (hereinafter the “Written Request 1”). The Call Option 1 is validly exercised
if the Written Request 1 is received by the Beneficiary within the end of the Lock-up Period subsequent to the Vesting Period during which the Shares object of the Call Option 1 have been assigned.

  

	10.3	 Through the subscription of the Agreement provided byart. 10., each beneficiary undertakes unconditionally and
irrevocably to sell to SG, at the Sale Price as determined under the art. 11 of this Regulation, the total number or a portion of the Shares and/or the total number or a portion of the Shares Additionally Assigned, including all the related rights,
the property of which will be assigned by SG as assignment free of charge related to each Vesting Period, if SG expresses in writing the will to buy those Shares and/or Shares Additionally Assigned through the exercise the Call Option 2, granted to
SG through the subscription of the above mentioned Agreement, the exercise of which depends, with a suspensive effect, if at least one of events provided by art. 13.1 and 13.2 of this Regulation occurs. 

 

	10.4	 The Call Option 2 will be exercised by SG by sending to the Beneficiary, to the address and in the manner
specified at the art. 14, a written communication (hereinafter the “Written Request 2”) containing the will to exercise the Call Option 2 and the indication of the conditions for applying the Call Option 2, the number of Shares and
or Shares Additionally Assigned object of the Call Option 2, the Sale Price and as well as of the date when and the place where all the relevant formalities related to the transfer of the ownership of the above mentioned Shares and or Shares
Additionally Assigned will be performed. The Call Option 2 is correctly exercised if the Written Request 2 is sent by SG to the Beneficiary within 2 years and 30 days from the end of the Lock-up Period
subsequent to the Vesting Period in relation to which the Shares and or Shares Additionally Assigned object ot the Call Option 2 were assigned 

  

	10.5	 The administrative body of SG may choose, at its discretion and for specific and justified events, not to
exercise the Call Option 1 and the Call Option 2. 

	11.	 SALE PRICE OF THE BENEFICIARIES’ SHARES 

11.1 In all cases in which SG will proceed: 
  

	 	•	 	 To exercise, fully or partially, the Call Option 1 of the Shares with reference to each Vesting Period, and/or

  

	 	•	 	 To exercise, fully or partially, the Call Option 2 of the Shares and/or of the Shares Additionally Assigned with
reference to each Vesting Period 

 the Sale Price will be calculated applying the following formula: 

Sale price of the Shares Assigned = (V * N * 50%) – D 

Sale price of the Shares Additionally Assigned = (V° * N° * 50%) – D° 

where 
 V = Value of the Shares
subject to the Call Option 1 and/or to the Shares subject to the Call Option 2 exercise. This value is the same calculated for determining the in kind income received by the Beneficiary at the time of the free assignment of the Shares at the
beginning of each Vesting Period; 
 V° = Value of the Shares Additionally Assigned subject to the Call Option 2 exercise. This value is
the same calculated for determining the in kind income received by the Beneficiary at the time of the free assignment of the Shares Additionally Assigned at the beginning of each Vesting Period; 

N = number of Shares subject to the Call Option 1 and/or to the Shares subject to the Call Option 2 exercise; 

N° = number of Shares Additionally Assigned subject to the Call Option 2 exercise; 

D = amount of the dividends (net of withholding tax due at the time of the payment by SG), related to the Shares subject to the Call Option 1
and to the Shares subject to the Call Option 2,distributed by SG and received by the Beneficiary in the period between the date when the Beneficiary become the owner of the Shares and exercise date of the Call Option 1 and/or the Call Option 2. 

D° = amount of the dividends (net of withholding tax due at the time of the payment by SG), related to the Shares Additionally Assigned
subject to the Call Option 2, distributed by SG and received by the Beneficiary in the period between the date when the Beneficiary become the owner of the Shares Additionally Assigned and exercise date of the Call Option 2. 

 

	12.	 TAX WARNINGS 

  

	12.1	 All the taxes related to the granting of Shares and Shares Additionally Assigned to each Beneficiary will be
borne by the Beneficiary of such shares. 

  

	12.2	 The Company and the Beneficiary declare and acknowledge, without any exception or reservation, that each of
them assumes the risk of the uncertainty connected with any variation of the value of: 

  

	 	i.	 the Shares occurred between the Assignment Date of Shares and the date when the Beneficiary may sell the Shares
to third parties other than SG at the end of the lock-up period, pursuant to this Regulation; 

	 	ii.	 the Shares Additionally Assigned occurred between the Assignment Date of Shares Additionally Assigned and the
date when the Beneficiary may sell the Shares Additionally Assigned to third parties other than SG at the end of the Lock-up period, pursuant to this Regulation. 

 

	12.3	 The Company has neither represented nor guaranteed to the Beneficiary any particular tax treatment of the
Shares and of the Shares Additionally Assigned which will be assigned free of charge, nor any capital gain the Beneficiary may earn in case of sale of the same Shares. Except for sanctions addressed to SG as tax substitute (“sostituto
d’imposta”), each Beneficiary will be exclusively responsible for any fiscal charge applicable to the operations object of this Regulation and of the operations put in place by the Beneficiary at the time in which the Beneficiary will
be entitled to freely dispose of the Shares and of the Shares Additionally Assigned. 

  

	13.	 CLAW BACK 

  

	13.1	 If within 2 years from the end of the Lock-Up Period, it appears that
the degree of achievement of the objectives set out in the BP SGP for a Vesting Period has been calculated on the basis of data that have subsequently been found to be incorrect due to unlawful conduct, malicious or negligent (gross negligence)
committed by one or more Beneficiaries, and the differences between the data used and the corrected data are such as to have caused the failure by SG to exercise Call Option 1, the Company will have the right to request from the Beneficiaries the
restitution, in whole or in part, of the Shares through the exercise of Call Option 2 at the Sale Price referred to in art. 11.. If at at the date when the Written Request 2 has been received the Beneficiary will not be anymore the owner of the
Shares subject to the Call Option 2, the Beneficiary will comply with the obligation to return the Shares by purchasing on the market a number of shares of SG corresponding to that of the Shares subject to the exercise of Call Option 2 or,
alternatively,will pay to SG an amount equal to the consideration derived from the sale of the Shares subject to the Call Option 2, net of any relevant fiscal charge with respect to the achieved capital gain, and deducted the amount equal to the
Sale Price (hereinafter the “Debt Amount 1”). SG will be entitled to, fully or partially, set-off the credit equal to the Debt 1 with any amount owed to the Beneficiary. 

 

	13.2	 If within 2 years from the end of the Lock-Up Period, it appears that
the degree of achievement of the objectives set out in the BP SGP for a Vesting Period has been calculated on the basis of data that have subsequently been found to be incorrect due to unlawful conduct, malicious or negligent (gross negligence)
committed by one or more Beneficiaries, and that the discrepancies between the data used and the adjusted data caused the assignment to the Beneficiaries of a number of Shares Additionally Assigned exceeding the number the ones effectively due in
accordance with the adjusted data, the Company will have the right to request from the Beneficiaries the restitution, in whole or in part, of the Shares Additionally Assigned through the exercise of Call Option 2 at the Sale Price referred to in
art. 11 of this Regulation. If at the date when the Written Request 2 has been received, the Beneficiary will not be anymore the owner of the Shares Additionally Assigned subject to the Call Option 2, the Beneficiary will comply with the obligation
to return the Shares Additionally Assigned by purchasing on the market a number of shares of SG corresponding to that of the Shares Additionally Assigned subject to the exercise of Call Option 2 or, alternatively, will pay to SG the value an amount
equal to the consideration derived from the sale of the Shares 

	 	
Additonally Assigned subject to the exercise of the Call Option 2, net of any relevant fiscal charge with respect to the achieved capital gain, and deducted the amount equal to the Sale Price
(hereinafter the “Debt Amount 2”). SG will be entitled to, fully or partially, set-off the credit equal to the Debt 2 with any amount owed to the Beneficiary. 

 

	14.	 NOTICES 

  

	14.1	 All notices requested or allowed by this Regulation will be regarded as duly executed if sent by certified
letter with return receipt or delivered by hand with receipt or sent by telefax confirmed by certified letter with return receipt, to the following addresses: 

 

	 	-	 if to SG: to Piombino Dese (PD), via Molinella 17, to the Attention of the Chairman of the SG’s: Board of
Directors; 

  

	 	-	 if to the Beneficiary: to the address indicated on the payroll of the company of the SG Group with which the
Beneficiary has the employment relationship, or, in the alternative, to the address indicated in the contract governing the employment relationship, or, in the further alternative, at the place where the Beneficiary carries out his/her duties for
the company of the SG Group or at the other address eventually indicated in the Agreement. 

  

	14.2	 The notices will be regarded as received upon the date indicated in the return receipt or, if sent by telefax
(after the receipt of the certified letter) on the second Business Day following the day of sending the telefax as resulting from the confirmation’s message. 

 

	15.	 APPLICABLE LAW AND JURISDICTION 

 

	15.1	 This Regulation is subject to and shall be assessed according with Italian law. 

 

	15.2	 Any dispute arising in connection with the Stock Grant Plan, whether for its interpretation or for its
execution, validity or termination, shall be submitted to the judgment of a sole arbitrator appointed by the President of the Tribunal of the district in which the SG has its registered office within 30 days of the written request of the most
diligent party. The seat of arbitration shall be established, by the appointed arbitrator within the Province in which the Company has its registered office. The arbitrate shall be considered ritual (arbitrato rituale) and the arbitrator will
decide according to law, with the application, therefore, of art. 806 et seq. of the Italian Code of Civil Procedure. The arbitrator shall pronounce the arbitration award within one hundred and eighty days from the acceptance of the
appointment. 

  

	15.3	 Without prejudice to the previous art. 15.2, it is understood that any dispute arising deriving or related to
the Stock Grant Plan reserved by law to the Judicial Authority, the court with jurisdiction will be the Court of Padua. The Court of Padua will be also the court with jurisdiction in case of renunciation by the parties to the arbitration procedure.

  

	15.4	 The SG’s administrative body may modify this Regulation in accordance with the necessary adjustment to the
applicable laws and regulations, retaining the spirit and the purposes desired by this Plan. 

 Annexes: 
 A
– Five-year Strategic Business Plan. 
 B – Grant Letter. 

C –Additional Grant Letter. 
 D – Draft of Agreement.

 E – Definition of Ebitda 
 Piombino Dese, 4 marzo 2021

 Annex A 

[***] 
 Annex B 

SU CARTA INTESTATA STEVANATO GROUP S.P.A. 

Mr. 

c/o Stevanato Group S.p.A. 

Via Molinella 17 

35017 Piombino Dese (PD) 

Piombino Dese,     March 2021 

Subject: Restricted stock grant plan 2021-2027 - Grant Letter 

Dear Mr.
                        , 

we hereby inform you that the Shareholders’ Meeting of Stevanato Group S.p.A. (hereinafter referred to as “SG” or the
“Company”) on 4th March 2021 resolved to approve a share-based incentive plan, named Restricted Stock Grant Plan 2021-2027 (hereinafter the “Stock Grant Plan” or the “SGP”), with the aim of involve
the persons who play a strategic role in SG and or in the companies belonging to the SG Group (hereinafter the “Beneficiaries” and, in the singular, the “Beneficiary”) in the economic and strategic development of
the Company and of the entire SG Group, aligning their interests to those of the shareholders and other stakeholders of the Company, during the period between 1st January 2021 and 31st December 2026. 

We are therefore pleased to inform you that you have been identified by the Board of Directors of SG, the body responsible for managing the SGP, as a
Beneficiary of the Stock Grant Plan. 
 The rules of the Stock Grant Plan are contained in the related regulation approved by the above mentioned SG
Shareholders’ Meeting on 4th March 2021 (hereinafter the “Regulation”), to be taken as a reference point for the full content, and the main aspects of which are summarized below. 

 The Stock Grant Plan provides for three two-years periods
(hereinafter the “Vesting Periods”) included, respectively, between the date of 1th January 2021 and 31st December 2022 (First Vesting Period), 1st January 2023 and 31st December 2024 (Second Vesting Period) and 1st January 2025 and
31st December 2026 (Third Vesting Period), at the beginning of which a certain number of SG shares - linked with the achievement within the end of each Vesting Period of specific targets in terms of consolidated Revenues and Ebitda of the Company
(hereinafter the “Targets”) - will be assigned free of charge to the Beneficiaries.. 
 The SG shares assigned in each Vesting Period
(hereinafter the “Shares”) shall be registered to a Trustee company, identified by SG, or, in case of dematerialization of the Shares, deposited in an account/securities portfolio registered to the Trustee, and shall be subject to
the Prohibition to Sell and to the Selling Commitment in accordance with the Lock-up Period as defined by the Regulation. 

The transfer of ownership of the Shares will be finalized after the signing with each Beneficiary of an Agreement which binds the Beneficiaries to re-sell to SG, fully or partially, the Shares assigned to them in case the Targets provided for the Vesting Period in relation to which the Shares were assigned should not be totally or partially achieved. A similar
obligation is provided if, within the end of each Vesting Period, the employment relationship of indefinite duration with a company of SG group terminates for death, resignation, lawful dismissal or for a justified subjective reason, or the
self-employment in favour of a company of SG group terminates or (ii) the notice period for resignation, dismissal for just cause, justified reason of the Beneficiary or termination of the self-employment relationship of the Beneficiary is
running, unless after the above mentioned period and without interruptions, the establishment of a new work relationship of the Beneficiary at any title, or the renewal of the former one, with SG or with companies of SG Group has occurred. 

In the event that certain over-performances with respect to the company financial targets have been met, Beneficiaries will be granted, free of charge, an
additional number of SG Shares related to the Vesting Period in which the Targets were exceeded (hereinafter the “Shares Additionally Assigned”), and such Shares Additional Assigned will be subject to the time-limited Prohibition to
Sell. 
 At the end of the Lock-up Period related to each Vesting Period governed by the Regulation, the
Beneficiaries will be in the conditions to freely dispose of the Shares and the Shares Additionally Assigned related to such Vesting Period. 
 Given the
above, we are pleased to inform you that, in relation to the First Vesting Period of the Stock Grant Plan: 
  

	 	a)	 the number of Shares assigned to you free of charge is equal to
n.                (in words) (hereinafter the “Shares Assigned”); 

	 	b)	 the number of Additional Shares Assigned that will be transferred free of charge if at the end of the above
mentioned Vesting Period the Cumulative Final Ebitda exceeds the Ebitda Target related to this Vesting Period by at least 1% (one percent), will be determined according to the following formula: 

SAA = SA x (n*i). 
 where: 

 

	 	•	 	 ‘SA’ is the number of Shares Assigned mentioned in the previous paragraph a); 

 

	 	•	 	 ‘i’ is the increasing percentage of the Final Cumulative Ebitda compared with the Ebitda Target of the
aforementioned Vesting Period; 

  

	 	•	 	 ‘n’ is equal
to                 (in letters) 

  

	 	c)	 the Revenue Target and the Ebitda Target of the above mentioned Vesting Period are as follows:

 Revenue Target: 

Ebitda Target: 
  

	 	d)	 the formalities necessary to procure the transfer free of charge of the Shares Assigned’s ownership will
be carried out before the Notary                  on                  at (time), at.
                 (place); simultaneously with the transfer of ownership, you will arrange to carry out the fiduciary registration of these Shares as required by the
Regulation; 

  

	 	c)	 We remind you that SG is available, at your request, to provide you with an interest-bearing loan, in order to
the pay the tax and social security charges deriving from the free of charge assignment to your favor of the Shares Assigned’s. property. 

We remain at your disposal for any clarifications you may need. 

Best regards. 
 Stevanato Group S.p.A.

 Annex C 
 SU
CARTA INTESTATA STEVANATO GROUP S.P.A. 
 Mr. 

c/o Stevanato Group S.p.A. 

Via Molinella 17 

35017 Piombino Dese (PD) 

Piombino Dese,     
 Subjet:
Restricted stock grant plan 2021-2027 – Additional Grant Letter 

Mr.                        , 

as you know the Regulation of the Stock Grant Plan of which you are Benericiary provides that, if at the end of each Vesting Period the Final Cumulative
Ebitda will be at least 1% (one percent) greater than the Ebitda Target related to the same Vesting Period, with reference to such Vesting Period the Beneficiaries are granted for free the property of a certain number of Shares Additionally
Assigned, determined according to the following formula: 
 SAA = SA x (n*i). 

where: 
  

	 	•	 	 ‘SA’ are the Share assigned in the Vesting Period just concluded; 

 

	 	•	 	 ‘i’ is the increasing percentage of the Final Cumulative Ebitda compared with the Ebitda Target;

  

	 	•	 	 ‘n’ is equal
to                (in letters) 

 We are therefore pleased
to inform you that, following the verification carried out on                by the the SG’s Board of Directors regarding the achievement of the Target, in relation
to the First / Second / Third Vesting Period, you have acquired the right to obtain from the Company the free assignment of the property of n.                (in
letters) Shares Additionally Assigned. 

 The formalities necessary to procure the transfer free of charge of the Shares Additionally Assigned
ownership will be carried out before the Notary                  on                  at
(time), at                  (place); simultaneously with the transfer of the property, you will arrange to carry out the fiduciary registration of the Shares
Additionally Assigned or, in case of dematerialization of the SG’s shares, the deposit of the Shares Additionally Assigned in an account/ portfolio securities held in the name of the Trustee. 

We remind you that SG is available, at your request, to provide you with an interest-bearing loan, in order to the pay the tax and social security charges
deriving from the free of charge assignment to your favor of the Shares Additionally Assigned’s property. 
 Pursuant to the Agreement signed by you on
[            ], the Shares Additionally Assigned may not be transferred to any person or entity other than SG until the end of the Lock-up Period
(31.12 .            ), at the end of which you will be entitled to freely dispose of the above mentioned Shares Additionally Assigned.. 

We remain at your disposal for any clarifications you may need. 

Best regards. 
 Stevanato Group S.p.A. 

(The Chief Executive Officer) 

 Annex D 

AGREEMENT 
 This agreement
(hereinafter the “Agreement”) is signed on                between 

Stevanato Group S.p.A., an Italian Joint Stock Company with registered office in Piombino Dese (PD) in via Molinella 17, Italy, registration number in
the Padua Company Register, tax code and VAT number 01487430280 (hereinafter “SG” or the “Company”), in the person of the pro tempore legal representative 

and 

                , born in
                 on                 , resident in
                , Italian fiscal Code (hereinafter the “Beneficiary” and together with SG the “Parties” andeach individually a
“Party”), 
 given that 
  

	 	(A)	 on 4th march 2021 the Company approved the Restricted
Stock Grant Plan Stevanato Group S.p.A. 2021 - 2027 (hereinafter the “Stock Grant Plan” or “SGP”) together with the related regulation attached to this Agreement under Exhibit “A” (the
“Regulation”). Unless otherwise provided for in this Agreement, all terms contained herein with a capital letter referring to the Regulation have the same meaning attributed to them by the Regulation; 

 

	 	(B)	 by means of a Grant Letter delivered to the Beneficiary on
                , the Company communicated to the Beneficiary the number of Shares granted related to the First/Second/Third Vesting Period, the restrictions related to
those Shares, the criteria used for the assignment of the Shares Additionally Assigned, as well the main contents of this Regulation; 

  

	 	(C)	 art. 4.5. of the Regulation provides that the transfer free of charge to the Beneficiary of the property of the
Shares assigned in each Vesting Period will be carried out after the signing of a specific agreement pursuant to the art. 10.1 of the Regulation; 

  

	 	(D)	 the Parties intend to implement the provisions contained in art. 6, 9.1, 9.3, 10.1 and 10.2 of the Regulation.

 Given the above, which are considered an integral and substantial part of this Agreement, the Parties agree and stipulate the
following: 
 Article 1 – The Call Option 1  
  

	 	1.1	 By signing this Agreement the Beneficiary undertakes unconditionally and irrevocably to sell to SG, at
the sale price as determined under the art. 11 of the Regulation (hereinafter the “Sale Price”), the total number of, or a portion of, the Shares, including all the related rights,

	 	
the property of which will be transferred free of charge by SG to the Beneficiary as a consequence of the assignment related to the First/Second/Third Vesting Period covered by the SGP, if SG
expresses in writing the will to buy such Shares through the exercise the Call Option 1, granted to SG by the Beneficiary through the signing of this Agreement. 

  

	 	1.2	 The exercise of the Call Option 1 by SG depends, with a suspensive effect, if at least one of the following
events occurs: 

  

	 	a)	 after the date when the Beneficiary becomes the owner of the Shares assigned free of charge related to the
Vesting Period indicated in art. 1.1 and within the end of such Vesting Period, (i) the employment relationship of indefinite duration with a company of SG group terminates for death, resignation, lawful dismissal or for a justified subjective
reason, or the self-employment in favour of a company of SG group terminates, (ii) the notice period for the resignations, lawful dismissal or for a justified subjective reason or termination of the self-emplyed relationship is running, unless
after the above-said period and without interruptions, the establishment of a new work relationship, at any title, or the renewal of the former one, with SG or with companies of SG Group has occurred. Any of the abovementioned events allows SG to
exercise the Call Option 1 of the Shares owned by the Beneficiary, or by the heirs in case of death of the Beneficiary, as a result of the assignment relating to such Vesting Period. For the purpose of evaluating the occurrence of the abovementioned
circumstances the following rules apply: 

  

	 	i.	 the employment relationship of indefinite duration with, or the self-employment in favor of, a company of SG
group shall be deemed as terminate at the date of termination of the aforesaid relationship becomes effective; 

  

	 	ii.	 the notice period will be effective on the date of receipt by the Company of the resignation letter or by the
addressee of the layoff communication in case of lawful dismissal or for a justified subjective reason or by the communication of termination of the self-employed relationship; 

 

	 	iii.	 the death of the Beneficiary that occurred prior to the end of the Vesting Period in which the Shares were
assigned shall be regarded as termination of the employment relationship which is relevant for the exercise by SG’s of the Call Option 1; 

  

	 	b)	 within the end of the Vesting Period indicate in art. 1.1 the Revenues Targets and/or Ebitda Targets have not
been fully or partially achieved, on the basis of SG’s consolidated financial statements as of December 31 of each year as part of the Stock Grant Plan period, presented to SG’s Shareholders’ Meeting upon the approval of
financial statements. After the Revenue Targets and/or Ebitda Targets verification, the Call Option 1 may be exercised by SG for: 

  

	 	i.	 the 15% of the Shares assigned free of charge in in such Vesting Period, if the Final Cumulative Revenues
reached at least 95%, but not exceed 

	 	
100%, of the Revenues Target under the BP SGP relating to the two-year period of such Vesting Period;the 30% of the Shares assigned free of charge in such
Vesting Period, if the Final Cumulative Revenues reached at least 85%, but not exceed 95%, of the Revenues Target under the BP SGP relating to the two-year period of such Vesting Period; 

 

	 	ii	 the 100% of the Shares assigned free of charge in such Vesting Period, if the Final Cumulative Revenues reached
at least 85% of the Revenues Target under the BP SGP relating to the two-year period of such Vesting Period; 

  

	 	ii.	 the 10% of the Shares assigned free of charge in such Vesting Period, if the Final Cumulative Revenues are
equal or exceed 100% of the Revenues Target under the BP SGP relating to the two-year period of such Vesting Period but the Final Cumulative Ebitda is lower than 90% of the Ebitda Targets under the BP SGP
relating to the two-year period of such Vesting Period; 

  

	 	iii.	 the percentages above indicated under points (i) and (ii), related to quota subject to the Call Option 1
exercised by SG, will be increased respectively to 30% and to 60% in case the Final Cumulative Ebitda is lower than 90% of the Ebitda Target under the BP SGP relating to the two-year period of such Vesting
Period; 

 If, with respect to the application of the percentages above indicated, it results that the calculated number
of the Shares subject to the Call Option 1 is expressed in decimals, this number will be rounded up to units, if the decimals are equal or exceed fifty cents, or down to units, if the decimals are lower than fifty cents. 

Article 2 – The Call Option 2 
  

	 	2.1	 By signing this Agreement the Beneficiary undertakes unconditionally and irrevocably to sell to SG, at
the sale price as determined under the art. 11 of the Regulation (hereinafter the “Sale Price”), the total number of, or a portion of, the Shares Additionally Assigned, including all the related rights, the property of which will be
transferred free of charge by SG to the Beneficiary as a consequence of the assignment related to the First/Second/Third Vesting Period covered by the SGP, if SG expresses in writing the will to buy such Shares Additionally Assigned through the
exercise the Call Option 2, granted to SG by the Beneficiary through the signing of this Agreement. 

  

	 	2.2	 The exercise of the Call Option 2 by SG depends, with a suspensive effect, if at least one of the
following events occurs: 

  

	 	a)	 If within 2 years from the end of the Lock-Up Period subsequent to the
Vesting Period indicated in art. 1.1, it appears that the degree of achievement of the objectives set out in the BP SGP for such Vesting Period has been calculated on the basis of data

	 	
that have subsequently been found to be incorrect due to unlawful conduct, malicious or negligent (gross negligence) committed by one or more Beneficiaries, and the differences between the data
used and the corrected data are such as to have caused the failure by SG to exercise Call Option 1 with regard to all the, or part of the, Shares assigned with reference to such Vesting Period; 

 

	 	b)	 If within 2 years from the end of the Lock-Up Period subsequent to the
Vesting Period indicated in art. 1.1, it appears that the degree of achievement of the objectives set out in the BP SGP for such Vesting Period has been calculated on the basis of data that have subsequently been found to be incorrect due to
unlawful conduct, malicious or negligent (gross negligence) committed by one or more Beneficiaries, and the differences between the data used and the corrected data are such as to have caused the assignment to the Beneficiaries of a number of Shares
Additionally Assigned exceeding the number the ones effectively due in accordance with the adjusted data. 

 Article 3 – The
Exercise of Call Option 1  
  

	 	3.1	 The Call Option 1 will be exercised by SG by sending to the Beneficiary, to the address and in the
manner specified in art. 14, a written communication containing the will to exercise the Call Option 1 and the indication of the conditions that legitimate the Call Option 1 exercise, the number of Shares object of the Call Option 1, the Sale Price
and as well as of the date when and the place where all the relevant formalities related to the transfer to SG of the ownership of the abovementioned Shares will be performed (hereinafter the “Written Request 1”). The Call Option 1
is validly exercised if the Written Request 1 is received by the Beneficiary within the end of the Lock-up Period subsequent to the Vesting Period indicated in art. 1.1. 

Article 4 – The Exercise of Call Option 2 
  

	 	4.1	 The Call Option 2 will be exercised by SG by sending to the Beneficiary, to the address and in the
manner specified at the art. 14, a written communication containing the will to exercise the Call Option 2 and the indication of the conditions that legitimate the Call Option 2 exercise, the number of Shares and/or Shares Additionally Assigned
object of the Call Option 2, the Sale Price and as well as of the date when and the place where all the relevant formalities related to the transfer to SG of the ownership of the above mentioned Shares and/or Shares Additionally Assigned will be
performed (hereinafter the “Written Request 2”). The Call Option 2 is validly exercised if the Written Request 2 is sent by SG to the Beneficiary within 2 years and 30 days from the end of the
Lock-up Period subsequent to the Vesting Period indicated in art. 1.1. 

  

	 	4.2	 If at the date when the Written Request 2 is received, the Beneficiary will not be anymore the owner of
the Shares and/or the Shares Additionally Assigned subject to the Call Option 2, the Beneficiary will comply with the obligation to return the Shares and/or the Shares 

	 	
Additionally Assigned by purchasing on the market a number of shares of SG corresponding to that of the Shares and/or the Shares Additionally Assigned subject to the exercise of Call Option 2 or,
alternatively, will pay to SG an amount equal to the consideration derived from the sale of the Shares and/or the Shares Additionally Assigned subject to the exercise of the Call Option 2, net of any relevant fiscal charge with respect to the
realized capital gain, and deducted the amount equal to the Sale Price (hereinafter the “Debt Amount”). SG will be entitled to, fully or partially, set-off the credit equal to the Debt Amount
with any amount owed to the Beneficiary. 

 Article 5 – Sale Price. Costs 

 

	 	5.1	 The Sale Price of the Shares subject to the exercise of Call Option 1 and of the Shares and/or the
Shares Additionally Assigned subject to the Exercise of Call Option 2 will be determined pursuant to art. 11 of the Regulation. 

  

	 	5.2	 With reference to the exercise of Call Option 1 and Call Option 2 and all the relevant formalities
related to the to the transfer of the property of the Shares and/or the Shares Additionally Assigned object of such exercise, the costs and the expenses related to assistance and consulting services rendered by experts appointed by each of the Party
will be borne by the appointing Party. The applicable taxes related to such transfer of property will be borne by the Beneficiary, while the costs and the expenses (i.e., notary fee and registration tax) related to the transfer of property of the
Shares and/or Shares Additionally Assigned subject to the exercise of Call Option 1 and Call Option 2 will be equally divided by the Parties. 

Article 6 – Prohibition to Sell 
  

	 	6.1	 The Shares of which the Beneficiary has acquired the property as a result of the free assignment related
to the Vesting Period indicated in art. 1.1, may not be transferred by the Beneficiary, or by his/her heirs in the event of the death of the Beneficiary, to individuals and/or entities other than SG until the end of the Lock-up Period, following to the Vesting Period indicated in art. 1.1 and in any case until the time of transfer to SG of the Shares as a result of the Call Option 1 timely exercised by SG pursuant to the
Regulation. 

  

	 	6.2	 The Shares Additionally Assigned, the ownership of which will be transferred to the Beneficiary if the
conditions provided for the Additional Assignment Free of Charge related to the Vesting Period indicated in art. 1.1 are met, may not be transferred by the Beneficiary, or by his/her heirs in case of death of the Beneficiary, to any person or entity
other than SG until the end of the Lock-up Period- following such Vesting Period. 

	 	6.3	 Until the end of the Lock-up Period following the Vesting Period
indicated in art. 1.1 the Beneficiary shall maintain the Shares and/or the Shares Additionally Assigned free from any possible option and pre-emption right or any other restriction or limitation, either
contractual and/or non-contractual including, but not limited to, absence of any encumbrance such as pledge, or other interests as warranty (“interessi in garanzia”) due or granted to third parties,
or foreclosure, preventive seizure or other type of charge of any other nature, except for those arising from the by-laws of SG and/or by the Regulation and/or by explicit and particular authorizations
resolved by the administrative body of SG. 

 Article 7 – Trustee Mandate 

 

	 	7.1	 The Shares assigned free of charge to the Beneficiaries in relation to the Vesting Period indicated in
art. 1.1 and the Shares Additional Assigned to the Beneficiaries related to such Vesting Period shall be, at the time of the property transfer to the Beneficiary, registered to a Trustee company identified by SG, or, in case of dematerialization of
the SG shares, deposited into an account/securities portfolio registered to the Trustee. The Beneficiary will have to grant to the Trustee a fiduciary mandate which will be irrevocable since it will be granted also in the Company’s interest, to
manage the Shares during such Vesting Period and the Shares Additionally Assigned related to such Vesting Period in its own name and on behalf of the Beneficiary, pursuant to art. 1723 al. 2 of the Italian Civil Code, as well as to monitor the
proper compliance with the Regulation and with the agreements already executed and/or to be executed between the Beneficiary and the Company in pursuant to the Regulation. 

 

	 	7.2	 The Trustee Mandate under art. 7.1 related to the Shares assigned in the Vesting Period indicated in
art. 1.1 will be valid: 

  

	 	a)	 until the end of the Lock-up Period subsequent to such Vesting Period,
if within that deadline the Beneficiary has not received the Written Request 1, containing the will expressed by SG to exercise the Call Option 1 related to such Shares; 

 

	 	b)	 until the date of the transfer of the property of the Shares to SG deriving from the timely exercise of the
Call Option 1 of such Shares by SG, in any other case. 

  

	 	7.3	 The Trustee Mandate governed by the art. 7.1 related to the Share Additionally Assigned to the
Beneficiaries with reference to the Vesting Period indicated in art. 11 in which the conditions provided for the Additional Assignment Free of Charge are met, will be valid until the end of the Lock-up Period
subsequent to such Vesting Period. 

 Article 8 – Transfer of the Agreement 

 

	 	8.1	 Each Party may not transfer this Agreement, and as well any rights deriving from the Agreement, without
the consent of the other Party. 

 Article 9 – Absence of Encumbrance 

 

	 	9.1	 The Beneficiary declares and guarantees that he/she is not currently bound and that he/she will not be
bound in the future to contracts or otherwise in any relationship incompatible with the proper fulfilment of the obligations assumed with the signing of this Agreement. 

Article 10 – Duration, Lock-up Period 

 

	 	10.1	 This Agreement will be valid and effective from the date of the signing until the end of the 5th year subsequent (hereinafter the “Duration”). 

 Article 11 –
Miscellaneous 
  

	 	11.1	 The premises are considered an integral and substantial part of this Agreement. 

 

	 	11.2	 All terms contained in this Agreement referring to the concept of “clear days”, meaning complete days
not including, in accordance with the valid expiring of the provided period, the day on which the period begins and the day on which the period ends. 

  

	 	11.3	 Any modifications to the provisions contained in this Agreement may be carry out only with the written consent
of the Parties. 

  

	 	11.4	 If one or more provision contained in this Agreement will be ruled as invalid, the remaining provisions will
remain valid and effective, unless the annulment of the invalid provisions will cause a significant modification to the will and to the purposes expressed by the Parties signing this Agreement. In this case, the Parties will negotiate in good faith
the replacement of the invalid provisions, redefining the respective rights and obligations in accordance with the new situation. 

  

	 	11.5	 Any acceptance from one Party with reference to the behavior, by violating the provisions contained in this
Agreement, of the other Party is not to be considered as renunciation of the rights deriving from the provisions infringed and of the right to demand the proper fulfillment of the terms and conditions already provided. 

 

	 	11.6	 With reference to the rules concerning the protection of the personal data, the Parties mutually confirm to
have received the information in accordance with the Legislative Decree n. 101 of 10 august 2018. Each Party gives to the other one the consent to the treatment of its personal data, directly or indirectly, through third parties, pursuant to
the above mentioned Legislative Decree n. 101/2018, in accordance with the purposes of this Agreement. 

  

	 	11.7	 The Parties hereby undertake to protect the absolutely confidential nature of this Agreement to any third
party. 

	 	11.8	 For any aspects not disciplined by this Agreement the Parties make reference to the provisions contained in the
Regulation. 

 Article 12 – Notices 
  

	 	12.1	 All notices requested or allowed by this Agreement will be regarded as duly executed if sent by
certified letter with return receipt or delivered by hand with receipt or sent by telefax confirmed by certified letter with return receipt, and will be considered as valid when received to the following addresses: 

 

	 	-	 if to SG, to: 

  

	 	  	 Stevanato Group S.p.A. 

 

	 	  	 Via Molinella 17, 

  

	 	  	 Piombino Dese (PD), 

  

	 	  	 to the Attention of the Chairman of the SG’s: Board of Directors; 

 

	 	-	 if to the Beneficiary, to: 

or at the different address or fax number that each Party may communicate to the other after the date of this Agreement in accordance with the
preceding provisions, on the understanding that at the addresses mentioned above, or at the various addresses that may be communicated in the future, the parties also elect their domicile for any purpose related to this Agreement, including that of
any judicial service. 
 Article 13 – Law of the Agreement 
  

	 	13.1	 This Agreement is governed by the Italian law. 

Article 14 – Arbitration 
  

	 	14.1	 All disputes arising from this Agreement, including those relating to its validity, interpretation, execution
and termination, must be referred to the judgment of a single arbitrator, appointed by the President of the Court of Padua at the request of the most diligent Party. 

 

	 	14.2	 The arbitration, whose headquarters will be in Padua, will be ritual pursuant to Articles 806 and following of
the Italian Code of Civil Procedure and the arbitrator will judge according to law by applying the Italian law. The arbitrator shall pronounce the arbitration award within 180 (one hundred and eighty) days from acceptance of the appointment.

	 	14.3	 Without prejudice to the foregoing, it is understood that for any dispute arising from or relating to this
Agreement that is by law reserved to the jurisdiction of the Italian Judicial Authority, the Court of Padua will be exclusively competent. The Court of Padua will also be exclusively competent in case the Parties renunciate to the arbitration
competence. 

 Piombino Dese, 
 Stevanato
Group S.p.A. 
 (The Chairman) 

  
 8 

 The Parties acknowledge that this Agreement has been negotiated between the Parties in its entirety. In any
case, to the extent necessary, for the purposes of Articles 1341-1342 of the Italian Civil Code. the Beneficiary specifically approves the following clauses: art. 1 (The Call Option 1), 2 (The Call Option 2), 5 (Sale Price. Costs), 6 (Prohibition to
Sell), 7 (Trustee Mandate), 8 (Transfer of the Agreement), 9 (Absence of Encumbrance), 10 (Duration, Lock-up Period), 13(Law of the Agreement) and 14 (Arbitration). 

  
 9 

 Exhibit A 

- the Regulation - 

 Annex E 

EBITDA and Adjusted EBITDA 
 Ebitda is defined as net profit
before income tax expenses, net financial expenses, including share of profit of associates, amortization and depreciation. Adjusted Ebitda is defined as Ebitda as adjusted for certain income and costs, which are significant in nature, expected to
occur infrequently, and that 
  

	
	 Net profit (+)

	 Income tax expense (+)

	 Net financial expenses (+)

	 Amortization and depreciation (+)

	 EBITDA

	 Revenus (-) Costs (+) not reflective of ongoing operational activities

	 Adjusted EBITDA

 management considers not reflective of ongoing operational activities of the company. 

In order to verify the achievement of the Ebitda Targets, provided by the Regulation, the Adjusted Ebitda will be considered. In any case, the adjusted Ebitda
to be considered will be the one represented in the SG Group’s consolidated annual financial statements and communicated to institutional investors.Contract
Manufacturing Agreement

 

This
Contract Manufacturing Agreement (the “Agreement”) is entered into as of January 1, 2021 (the “Effective Date”),
by and between KES SCIENCE & TECHNOLOGY INC., a Georgia corporation, at 3625 Kennesaw North Industrial Parkway, Kennesaw,
Georgia 30144 (“KES”), and AKIDA HOLDING, LLC, a Florida limited liability company, at 2300 Marshpoint Road,
Suite 202, Neptune Beach, Florida 32266 (“Akida”). KES and Akida are each a “Party” and collectively,
the “Parties.”

WHEREAS,
KES is the manufacturer of that certain product line of AiroCide hydrocarbon gas and airborne pathogen removal systems, developed
exclusively for Akida and funded by KES, as more particularly described in Exhibit “A” (the “Products”);

WHEREAS,
Akida will enter into an Asset Purchase Agreement (the “Purchase Agreement”) with Applied UV, Inc. (“Parent”)
and SteriLumen, Inc., the wholly-owned subsidiary of Parent (the “Purchaser”) which provides for the sale of the AiroCide
assets from Akida to the Purchaser;

WHEREAS,
Akida wishes to purchase and have its successor in interest have the right to purchase the Products from KES and KES wishes to
manufacture the Products to Akida and its successor in interests, on the terms and conditions hereinafter set forth.

NOW,
THEREFORE, in consideration of the mutual covenants, terms, and conditions set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. 
Manufacture Products.

1.1 
Manufacture. Subject to the terms and
conditions of this Agreement, KES shall manufacture the Products, including ordering and management of required components to
make the Products, as set forth in Exhibit “A” as amended from time to time. Notwithstanding the foregoing, Products
shall require the issuance of purchase orders by Akida as hereinafter provided. It is expressly acknowledged and agreed that this
Agreement does not itself provide for the purchase of any quantity of any Products, nor an obligation by KES to manufacture any
quantity of Products. The terms and conditions of this Agreement shall govern all purchases of the Products in Exhibit A. Any
additional, contrary or different terms contained in any purchase order, acknowledgement, confirmation, invoice or communication,
and any other attempt to modify, supersede, supplement or otherwise alter this Agreement, are deemed rejected by the other Party
and will not modify this Agreement or be binding on the Parties unless such terms have been fully approved in a signed writing
by authorized representatives of both Parties. The bill of materials and manufacturing costs for each Product is set forth on
Exhibit B, which may be amended from time to time if Akida or KES sources lower or raise cost materials.

1.2 
Forecasts and Inventory Planning. On a
monthly basis, Akida will provide KES with a nonbinding rolling forecast for the following six (6) months. Forecasts are for informational
purposes only and do not create any binding obligations on behalf of either Party. KES will be responsible for material planning
to meet the rolling forecast and mutually agreed upon service levels for Products. KES will promptly notify Akida if KES becomes
aware that KES cannot meet the rolling forecast. However, a failure to provide such notice shall not constitute a breach under
this Agreement.

1.3 
No Right to Manufacture and Sell Products to Other Parties.
Except as allowed by the Intellectual Property Assignment and License Agreement dated as of the date hereof, between the Parties
(the “License”) KES shall not offer, sell, provide or manufacture the Products or any other products containing the
Catalyst (except as provided for in the License), to or for any person or entity other than Akida, or Akida’s permitted
successors and assigns. This Section will survive expiration or termination of this Agreement.

2. 
Ordering Procedure.

2.1 
Purchase Orders. Akida
shall make all purchases of the Products by submitting written purchase orders or electronically transmitted sales orders
(each, a “Purchase Order”) to KES through a mutually agreed upon automated ordering system. KES
will acknowledge and confirm each accepted Purchase Order within one (1) business day. Each Purchase Order shall specify the quantity
of the Products ordered, the place of delivery and the delivery date therefore, which date will be jointly set by Akida and KES.
KES will not unreasonably delay any manufacturing or related component purchasing once a Purchase Order is accepted.

2.2 
Cancellation of Purchase Orders. At any
time after KES has accepted a Purchase Order, Akida may cancel such Purchase Order only upon KES’s written approval.

3. 
Shipment, Delivery, Acceptance, and Inspection.

3.1 
Shipment and Delivery Requirements. KES
shall manufacture, assemble, pack, mark, and ship Products strictly in the quantities and by the methods, to the delivery locations
and by the delivery dates, specified in this Agreement or an applicable Purchase Order.

3.2 
 Transfer of Title and Risk of Loss. Title to Products and risk of loss to Products shipped under a Purchase Order passes
to Akida upon receipt and acceptance by the shipping carrier at the place of origin (e.g. the manufacturing or storage facility
of KES).

3.3 
Packaging and Labeling. KES shall properly
pack, mark, and ship Products as instructed by Akida and otherwise in accordance with applicable law and industry standards and
shall provide Akida with shipment documentation showing the Purchase Order number, KES’s identification number for the subject
Products, the quantity of pieces in shipment, bill of lading number, and such other information as Akida reasonably requests.

3.4 
Inspection. Products are subject to Akida’s
inspection and approval or rejection of Nonconforming Products (defined as Products that are out of specification, non-functional,
or functioning improperly) notwithstanding Akida’s prior receipt of or payment for the Products. Akida shall have fourteen
(14) days following delivery of the Products (“Inspection Period”), to inspect all Products received under this Agreement
and to inform KES, in writing, of Akida’s rejection of any Nonconforming Products. For purposes of this Agreement, “Nonconforming
Products” means any products received by Akida from KES that: (a) do not conform to the model number listed in the applicable
Purchase Order or fully conform to the specifications for such model number; (b) on visual inspection, Akida reasonably determines
are otherwise defective; or (c) exceed the quantity of Products ordered by Akida pursuant to the applicable Purchase Order. Akida
may return to KES any or all units of rejected Products that constitute Nonconforming Products because they exceed the quantity
stated in the applicable Purchase Order. If Akida rejects any other Nonconforming Products, Akida may elect to (a) require KES,
at KES’s sole cost, to replace the rejected Products at the location specified by Akida (which may include KES’s location,
Akida’s location or the location of a third party), or (b) retain the rejected Products; in each case without limiting the
exercise by Akida of any other rights available to Akida under this Agreement or pursuant to applicable law. All returns of Nonconforming
Products to KES are at KES’s sole risk and expense, so long as the return shipping is coordinated by KES. Products that
are not rejected within the Inspection Period will be deemed to have been accepted by Akida; provided, however, that Akida’s
acceptance of any Products will not be deemed to be a waiver or limitation of KES’s obligations pursuant to this Agreement
(or any breach thereof).

4. 
Price and Payment.

4.1 
Price. Akida shall purchase the Products
from KES at the prices set forth on Exhibit “A” attached hereto (“Prices”). Akida is solely responsible
for all costs and expenses relating to, transporting, loading and unloading, customs, taxes, tariffs and duties, insurance and
any other similar financial contributions or obligations relating to the production, manufacture, sale, and delivery of the Products.

4.2 
Invoices. KES shall submit invoices to
Akida upon shipment of Product to the address set forth in the applicable Purchase Order. Each invoice for Products must set forth
in reasonable detail the amounts payable by Akida under this Agreement and contain the following information, as applicable: Purchase
Order number, quantity and identification of Products shipped, serial numbers (if applicable), carrier name, ship-to address,
bill of lading number, and any other information requested by Akida for identification and control of the Products.

4.3 
Payment. Except for any amounts disputed
by Akida in good faith, KES’s accurate and correctly submitted invoices will be payable within thirty (30) days following
Akida’s receipt of KES’s invoice. Any payment by Akida for Products will not be deemed acceptance of the Products
or waive Akida’s right to inspect. Akida shall make all payments in US dollars by check, wire transfer or automated clearing
house as instructed by KES.

4.4 
Setoff; Contingent or Disputed Claims.
Akida agrees to pay all undisputed charges under this Agreement without counter-claim, set-off or deduction. In the event that
Akida legitimately and reasonably disputes an invoiced amount, Akida will provide KES with written notice of the amount in dispute
and the basis for the dispute. KES agrees that it will work with Akdia to reasonably and expeditiously resolve the dispute within
a thirty (30) day period.

5. 
Term; Termination.

5.1 
Initial Term. The term of this Agreement
commences on the Effective Date and continues through December 31, 2022, unless it is earlier terminated pursuant to the terms
of this Agreement or applicable law (the “Initial Term”).

5.2 
Renewal Term. Upon expiration of the Initial
Term, the term of this Agreement will automatically renew for additional successive one (1) year terms unless either Party provides
written notice of non-renewal at least sixty (60) days prior to the end of the then-current term (each, a “Renewal Term”
and together with the Initial Term, the “Term”), unless any Renewal Term is earlier terminated pursuant to the terms
of this Agreement or applicable law. If the Initial Term or any Renewal Term is renewed for any Renewal Term(s) pursuant to this
section, the terms and conditions of this Agreement during each such Renewal Term will be the same as the terms in effect immediately
prior to such renewal. In the event either Party provides timely notice of its intent not to renew this Agreement, then, unless
earlier terminated in accordance with its terms, this Agreement terminates on the expiration of the Initial Term or then-current
Renewal Term, as applicable.

5.3 
Termination for Cause. Either Party may
terminate this Agreement for cause with immediate effect upon written notice to the other Party: (i) if such other Party fails
to perform any material obligation under this Agreement or otherwise materially breaches the Agreement, through no fault of the
Party initiating such termination, that remains uncured for thirty (30) calendar days following written notice to such Party
of such failure or breach; or (ii) if the Other Party becomes insolvent, is generally unable to pay, or fails to pay, its debts
as they become due, files a petition for bankruptcy or commences or has commenced against it proceedings relating to bankruptcy,
receivership, reorganization, or assignment for the benefit of creditors.

5.4 
Termination Without Cause. 

(a) 
During the Initial Term (and subject to its non-renewal right set forth in section 5.2), Akida may terminate this Agreement
for convenience: (i) upon six (6) months’ advance written notice of termination, provided such termination shall not be
effective before January 1, 2022; and (ii) payment of an early termination fee in the amount equal to ten percent (10%) of all
gross sales revenues of the Products sold from the termination date through December 31, 2022 (the “Early Termination Fee”).
Akida shall pay the Early Termination Fee on a monthly basis, no later than the twentieth (20th)
of the month, accompanied by an accounting of units sold and invoice price for the preceding month. 

(b) 
After the Initial Term, either Party may
terminate this Agreement for convenience upon giving sixty (60) days’ advance written notice of termination to the other
Party.

(c) 
During any Term, either Party may terminate this Agreement solely with respect to the manufacture and purchase of the Catalyst
(as defined in Exhibit “A”) upon six (6) months’ advance written notice of termination to the other Party.

5.5 
Effect of Expiration or Termination.  

(a) 
Immediately upon the effectiveness of a notice of termination, KES shall, unless otherwise directed by Akida, and subject to KES’s
obligation provide resourcing cooperation: (i) promptly terminate all performance under this Agreement and under any outstanding
Purchase Orders; (ii) transfer title and deliver to Akida all finished Products completed prior to effectiveness of the notice
of termination; and (iii) return to Akida all property furnished by or belonging to Akida or any of Akida’s customers, or
dispose of such other property in accordance with Akida’s instructions (provided that Akida will reimburse KES for the actual,
reasonable costs associated with such disposal). Akida will purchase from KES any remaining raw materials or work-in-progress
at cost with supporting invoices for any Purchase Orders that were placed by Akida and accepted by KES before termination or expiration
of this Agreement. KES agrees, if requested by Akida, to finish any work in progress that remains after it receives a termination
notice from Akida.

(b) 
The termination or expiration of this Agreement for any reason shall not release any Party hereto of any liability which at the
time of termination or expiration had already accrued to the other Party in respect to any act or omission prior thereto.

(c) 
Upon the expiration or earlier termination of this Agreement, each Party shall return to the other Party or destroy all documents
and tangible materials (and any copies) containing, reflecting, incorporating or based on the other Party’s Confidential
Information. In addition, each Party, upon the other Party’s written request, will certify in writing to such other Party
that it has complied with the requirements of this section.

5.6 
Resourcing Cooperation. Upon the expiration
or earlier termination of this Agreement for any reason, to the extent requested by Akida in writing, KES will take such actions
as may be reasonably required by Akida, at Akida’s sole cost and expense, to transition production of Products from KES
to an alternative manufacturer/supplier without production disruptions, including without limitation, manufacturing, delivering
and selling to Akida a sufficient inventory bank of Products to ensure that the transition will proceed smoothly and without interruption
or delay, with pricing equivalent to the pricing in effect immediately before expiration or termination.

6. 
Certain Obligations of KES.

6.1 
Quality.  

(a) 
KES shall meet or exceed Akida’s quality standards for the Products as adopted by Akida from time to time, and which are
provided by Akida to KES in writing.

(b) 
KES shall provide commercially reasonable support as requested by Akida to address and correct quality concerns. In addition to
its other rights and remedies, Akida may hold KES responsible for costs associated with quality-issue investigation and containment
to the extent caused by KES’s acts or omissions.

(c) 
KES shall take reasonable steps to meet or exceed any U.S. Food & Drug Administration and other relevant quality system standards
applicable to the manufacturing of the Products.

6.2 
Maintenance of Equipment. Unless otherwise agreed to by Akida in writing, KES, at its sole expense, shall furnish, keep
in good condition, and replace when necessary all equipment and other items necessary for the production of the Products.

6.3 
Prohibited Acts. KES shall not:

(a) 
take any action that interferes with or challenges Akida’s intellectual property rights, including Akida’s ownership
or exercise thereof; or

(b) 
alter, obscure or remove any of Akida’s
trademark or copyright notices or any other proprietary rights notices placed on the products purchased under this Agreement (including
Products), marketing materials or other materials.

7. 
Compliance with Laws. 

7.1 
Compliance. KES shall at all times comply
with all laws applicable to this Agreement, KES’s operation of its business and the exercise of its rights and performance
of its obligations hereunder. Without limitation of the foregoing, KES shall ensure the Products and any related packaging, conform
fully to any applicable law. KES shall also manufacture the Products in adherence to the manufacturing specifications and release
specifications provided by Akida and will maintain effective quality systems that minimize the potential for product quality,
regulatory and compliance issues.

7.2 
Permits, Licenses, and Authorizations.
KES shall obtain and maintain all permits necessary for the exercise of its rights and performance of KES’s obligations
under this Agreement, including any permits required for the import of Products or any raw materials and other manufacturing parts
used in the production and manufacture of the Products, and the shipment of hazardous materials, as applicable.

8. 
Representations and Warranties; Product Warranty. 

8.1 
KES’s Representations and Warranties.
KES represents and warrants to Akida that:

(a) 
it is a limited liability company, duly organized, validly existing and in good standing under the laws of Georgia;

(b) 
it is duly qualified to do business and is in good standing in every jurisdiction in which such qualification is required for
purposes of this Agreement;

(c) 
it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder; and

(d) 
the execution of this Agreement by its representative whose signature is set forth at the end of this Agreement and the delivery
of this Agreement by KES, have been duly authorized by all necessary action on the part of KES.

8.2 
Akida’s Representations and Warranties.
Akida represents and warrants to KES that:

(a) 
it is a limited liability company, duly organized, validly existing and in good standing under the laws of Florida;

(b) 
it is duly qualified to do business and is in good standing in every jurisdiction in which such qualification is required for
purposes of this Agreement;

(c) 
it has the full right, power and authority to enter into this Agreement and to perform its obligations hereunder; and

(d) 
the execution of this Agreement by its representative whose signature is set forth at the end of this Agreement and the delivery
of this Agreement by Akida, have been duly authorized by all necessary action on the part of Akida.

8.3 
Product Warranty. KES warrants to Akida
(the “Product Warranty”) that:

(a) 
for a period of one (1) year from the date of shipment of the Products (the “Warranty Period”), the Products will
conform, in all material respects, to the specifications, standards, quality and performance requirements furnished, specified
or approved by Akida for the Products and be free from significant defects in material and workmanship; and

(b) 
each of the Products will be new and conveyed by KES to Akida with good title, free and clear of all encumbrances.

The
Product Warranty does not apply to any Product that has been subjected to abuse, misuse, neglect, negligence, accident, improper
testing, improper installation, improper storage, improper handling, abnormal physical stress, abnormal environmental conditions
or use contrary to any instructions issued by KES.

8.4 
Withdrawal or Recall of Products. If Akida
or any governmental authority determines that any Products sold to Akida are defective and a recall campaign is necessary, Akida
will have the right to implement such recall campaign and return defective products to KES or destroy such Products, as determined
by Akida in its reasonable discretion, at KES’s sole cost and risk so long as it is determined by agreement of the Parties
or a determination through arbitration (pursuant to the arbitration provision of this Agreement) that the recall is a result of
KES’s performance under this Agreement. If a recall campaign is implemented, and it is determined by agreement of the Parties
or a determination through arbitration (pursuant to the arbitration provision in this Agreement) that the recall is a result of
KES’s performance under this Agreement, at Akida’s option and KES’s sole cost, KES shall promptly either: (a)
replace any defective products and provide such replacement Products to Akida or Akida’s designee; or (b) repair any defective
products by providing replacement components (rather than replacing the entire product) as long as such repair does not negatively
impact Akida’s customers. KES will be liable for all of Akida’s costs associated with any recall campaign if such
recall campaign is based upon a reasonable determination that the Products fail to conform to the warranties set forth in this
Agreement.

8.5 
DISCLAIMER OF OTHER REPRESENTATIONS AND WARRANTIES; NON-RELIANCE.
EXCEPT FOR THE PRODUCT WARRANTY SET FORTH IN SECTION 8.3: (A) NEITHER KES NOR ANY PERSON ON KES’S BEHALF HAS MADE OR MAKES
ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY WHATSOEVER, EITHER ORAL OR WRITTEN, INCLUDING ANY WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE,
ALL OF WHICH ARE EXPRESSLY DISCLAIMED, AND (B) AKIDA ACKNOWLEDGES THAT IT HAS NOT RELIED UPON ANY REPRESENTATION OR WARRANTY MADE
BY KES, OR ANY OTHER PERSON ON KES’S BEHALF, EXCEPT AS SPECIFICALLY PROVIDED IN SECTIONS 8.1 AND 8.3 OF THIS AGREEMENT.

9. 
Indemnification. 

9.1 
Indemnification. Subject to the terms
and conditions of this Agreement, KES (as “Indemnifying Party”) shall indemnify, defend and hold harmless Akida and
its officers, directors, employees, agents, affiliates, representatives, successors and assigns (collectively, “Indemnified
Parties”) against any and all losses, damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest,
awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys’ fees, fees and the costs
of enforcing any right to indemnification under this Agreement and the cost of pursuing any insurance providers, incurred by any
Indemnified Party (collectively, “Losses”), resulting from any third-party claim or any direct claim against Indemnifying
Party alleging:

(a) 
a breach or non-fulfillment of any of Indemnifying Party’s representations, warranties, or covenants set forth in this Agreement;

(b) 
any grossly negligent or more culpable act or omission of Indemnifying Party or any of its representatives (including any recklessness
or willful misconduct) in connection with Indemnifying Party’s performance under this Agreement; or

(c) 
any bodily injury, death of any person or damage to real or tangible personal property caused by the willful or grossly negligent
acts or omissions of Indemnifying Party or any of its representatives.

9.2 
Exceptions and Limitations on Indemnification.
Notwithstanding anything to the contrary in this Agreement, Indemnifying Party is not obligated to indemnify or defend any Indemnified
Party against any claim or corresponding Losses resulting directly from Indemnified Party’s gross negligence or more culpable
act or omission (including recklessness or willful misconduct).

10. 
NO LIABILITY FOR CONSEQUENTIAL OR INDIRECT DAMAGES.
IN NO EVENT SHALL EITHER PARTY OR THEIR REPRESENTATIVES BE LIABLE FOR CONSEQUENTIAL, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY,
PUNITIVE OR ENHANCED DAMAGES, OR LOST PROFITS OR REVENUES, ARISING OUT OF OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS
OF (A) WHETHER SUCH DAMAGES WERE FORESEEABLE, (B) WHETHER OR NOT THE PARTY WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND
(C) THE LEGAL OR EQUITABLE THEORY (CONTRACT, TORT OR OTHERWISE) UPON WHICH THE CLAIM IS BASED, AND NOTWITHSTANDING THE FAILURE
OF ANY AGREED OR OTHER REMEDY OF ITS ESSENTIAL PURPOSE.

11. 
Inspection and Audit Rights. KES hereby
grants to Akida access to KES’s premises (including KES’s manufacturing operations used in production of the Products)
and all pertinent documents and other information, whether stored in tangible or intangible form, including any books, records,
and accounts, in any way related to KES’s performance under this Agreement (including KES’s processes and procedures),
Products, or any payment or other transaction occurring in connection with this Agreement, for the purpose of auditing KES’s
compliance with the terms of this Agreement and any other agreements between Akida and KES, including KES’s charges for
Products, or inspecting or conducting an inventory of finished Products, work-in-process or raw-material inventory; provided that
any physical inventory inspection may take place no more frequently than semi-annually. KES agrees to cooperate fully with Akida
in connection with any such audit or inspection. KES shall maintain, during the Term and for a period of four (4) years after
the Term, complete and accurate books and records and any other financial information in accordance with GAAP. KES shall segregate
its records and otherwise cooperate with Akida so as to facilitate any audit by Akida.

12. 
Insurance. During the Term, KES shall,
at its own expense, maintain and carry in full force and effect, subject to appropriate levels of self-insurance, commercial general
liability insurance in a sum no less than $1,000,000 and statutory workers’ compensation insurance as required by applicable
law (including an “all states” endorsement) with financially sound and reputable insurers. Upon Akida’s written
request, KES shall provide Akida with a certificate of insurance evidencing the insurance coverage specified in this Section.
The certificate of insurance shall name Akida as an additional insured and loss payee. KES shall provide Akida with thirty (30)
days’ advance written notice in the event of a cancellation or material change in such insurance policy.

13. 
Miscellaneous. 

13.1 
Further Assurances. Upon a Party’s
reasonable request, the other Party shall, at its sole cost and expense, execute and deliver all such further documents and instruments,
and take all such further acts, necessary to give full effect to this Agreement.

13.2 
Relationship of the Parties. The relationship
between KES and Akida is solely that of vendor and vendee and they are independent contracting parties. Nothing in this Agreement
creates any agency, joint venture, partnership or other form of joint enterprise, employment or fiduciary relationship between
the Parties. Neither Party has any express or implied right or authority to assume or create any obligations on behalf of or in
the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any third party.

13.3 
Entire Agreement. This Agreement, including
and together with any related exhibits, schedules and the applicable terms of any Purchase Orders, constitutes the sole and entire
understanding and agreement of the Parties with respect to the subject matter contained herein and therein, and supersedes all
prior and contemporaneous understandings, agreements, proposals, discussions, representations and warranties, both written and
oral, with respect to such subject matter. If there is a conflict between the terms of this Agreement and of any exhibit, schedules
or purchase orders, the terms of this Agreement shall govern.

13.4 
Notices. All notices, requests, consents,
claims, demands, waivers and other communications under this Agreement (each, a “Notice”) must be in writing and addressed
to the other Party at its address set forth below (or to such other address that the receiving Party may designate from time to
time in accordance with this section). All Notices must be delivered by personal delivery, nationally recognized overnight courier
or certified or registered mail (in each case, return receipt requested, postage prepaid) or email (with confirmation of transmission).
Except as otherwise provided in this Agreement, a Notice is effective only (a) on receipt by the receiving Party, and (b) if the
Party giving the Notice has complied with the requirements of this Section.

If
to KES:

KES
SCIENCE &TECHNOLOGY INC.

3625
Kennesaw North Industrial Parkway

Kennesaw,
GA 30144

Attention:
John Hayman

Email:
jhayman@kesscience.com

 

If
to Akida:

AKIDA
HOLDING, LLC

2300
Marshpoint Road, Suite 202

Neptune
Beach, FL 32266

Attention:
David E. Kight

Email:
dkight@akidaholdings.com 

13.5 
Interpretation. The Parties drafted this
Agreement without regard to any presumption or rule requiring construction or interpretation against the Party drafting an instrument
or causing any instrument to be drafted. The exhibits, schedules, and attachments referred to herein are an integral part of this
Agreement to the same extent as if they were set forth verbatim herein.

13.6 
Headings. The headings in this Agreement
are for reference only and do not affect the interpretation of this Agreement.

13.7 
Severability. If any term or provision
of this Agreement is held void, voidable, invalid, illegal or unenforceable in any jurisdiction, no other provision of this Agreement
shall be affected as a result thereof, and the remaining provisions of this Agreement shall be valid and remain in full force
and effect as if such void, voidable, invalid, illegal or unenforceable provision had been omitted.

13.8 
Amendment and Modification. No amendment,
change, modification, alteration, addition to, rescission, termination or discharge of this Agreement is effective unless it is
in writing and signed by authorized representatives of both Parties.

13.9 
Waiver.  None of the terms of this
Agreement may be waived, in whole or in part, unless such waiver is in writing and signed by an authorized representative of both
Parties. Any waiver authorized on one occasion is effective only in that instance and only for the purpose stated and does not
operate as a waiver on any future occasion or any other provision of the Agreement. Any course of dealing between the Parties
or failure or delay in exercising any right, remedy, power or privilege or in enforcing any condition under this Agreement shall
not constitute a waiver or estoppel of any right, remedy, power, privilege or condition arising from this Agreement.

13.10 
Assignment. Akida may assign any of its
rights or delegate any of its duties under this Agreement to any person or entity in Akida’s sole discretion, upon written
notice to KES. KES hereby acknowledges that a condition precedent to the Purchase Agreement is the assignment of this Agreement
and all of Akida’s rights hereunder to the Purchaser and KES hereby consents to any such assignment and waives any requirement
of notice. KES may only assign its rights or delegate its duties under this Agreement to a wholly owned subsidiary or to a purchaser
of or successor to all or substantially all its assets (whether through sale, merger, restructuring or otherwise), upon written
notice to Akida. Notwithstanding the foregoing, KES may use third-party suppliers to fulfill its obligations under this Agreement.
Any purported assignment or delegation in violation of this section is null and void.

13.11 
Successors and Assigns. This Agreement
is binding on and inures to the benefit of the Parties and their respective permitted successors and permitted assigns.

13.12 
Third-Party Beneficiaries. The Parties
agree that the Parent and the Purchaser are third-party beneficiaries of all of rights and benefits hereunder and each may enforce
the provisions hereof as if it were a party hereto.

13.13 
Survivability. Terms and conditions that require performance after the termination or expiration of this Agreement, including
without limitation, use restrictions, limitations of liability, indemnification, and confidentiality provisions, will survive
any termination or expiration of this Agreement.

13.14 
Governing Law, Venue and Remedies. All
questions concerning the construction, validity, enforcement, and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts of law
thereof. If any dispute should arise between the parties that cannot be resolved informally, it shall be settled by arbitration
in the Delaware office of the American Arbitration Association before a panel of three arbitrators designated by the American
Arbitration Association in accordance with the Rules of the American Arbitration Association then obtaining in Delaware. The cost
of any arbitration proceedings and the prevailing Party’s attorneys’ fees shall be borne by the Party against whom
an award is made. The decision of the arbitrators shall be binding and conclusive upon the Parties. If the American Arbitration
Association shall not then be in existence, arbitration shall be settled by such other organization, if any, as shall then have
become the successor of said Association.

13.15 
Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES
AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE OUT OF OR RELATE TO THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT
OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. Each Party certifies
and acknowledges that (a) no representative of the other Party has represented, expressly or otherwise, that such other Party
would not seek to enforce the foregoing waiver in the event of a legal action, (b) such Party has considered the implications
of this waiver, (c) such Party makes this waiver voluntarily, and (d) such Party has been induced to enter into this Agreement
by, among other things, the mutual waivers and certifications in this Section.

13.16 
Attorneys’ Fees. In the event that either Party employs attorneys to enforce any right arising out of or relating to
this Agreement, the prevailing Party shall be entitled to recover its reasonable attorneys’ fees and costs.

13.17 
Force Majeure. No Party shall be liable
or responsible to the other Party, nor be deemed to have defaulted under or breached this Agreement, for any failure or delay
in fulfilling or performing any term of this Agreement, when and to the extent such party’s (the “Impacted Party”)
failure or delay is caused by or results from the following force majeure events (“Force Majeure Event(s)”): acts
of God, flood, fire, earthquake, hurricane, tornado, epidemic, pandemic, explosion, war, terrorism, riot, government order or
action, and other similar events beyond the reasonable control of the Impacted Party. The Impacted Party shall give notice to
the other Party as soon as practicable, stating the period of time the occurrence is expected to continue. The Impacted Party
shall use diligent efforts to end the failure or delay and ensure the effects of such Force Majeure Event are minimized. The Impacted
Party shall resume the performance of its obligations as soon as reasonably practicable after the removal of the cause. Notwithstanding
the forgoing, the other Party may terminate this Agreement upon written notice if the Impacted Party’s nonperformance continues
for a period of ninety (90) consecutive days.

13.18 
Counterparts. This Agreement may be executed
in counterparts, each of which is deemed an original, but all of which together is deemed to be one and the same agreement. A
signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission is deemed to have the same
legal effect as delivery of an original signed copy of this Agreement.

IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Effective Date.

KES
SCIENCE & TECHNOLOGY, INC.

 

By:
______________________________________

Name:
____________________________________

Title:
_____________________________________

Date:
_____________________________________

 

AKIDA
HOLDING, LLC

 

By:
______________________________________

Name:
David Kight

Title:
COO/CFO

Date:
_____________________________________

    	 	1	 

     

    

 

Exhibit
“A”

 

Products
and Prices: “Products” include:

a. 
HD product line consisting of the following models and accessories at the following prices:

	Unit
    Item #	Net
    Cost to Akida	Suggested
    Retail
	HD-1200	 $                  831.00	 $              1,440.00
	HD-1500	 $                  825.00	 $              1,440.00
	HD-25000	 $              1,480.80	 $              2,640.00
	HD-TITAN	 $              2,285.00	 $              4,220.00
	AIRO-PRO HO	 $                  468.00	 $                  645.00
	 	 	 
	Lamp
    & Filter Kit Item #	 	 
	HD-LAMP1200	 $                    90.70	 $                  139.00
	HD-LAMP1500	 $                    90.70	 $                  139.00
	HD-LAMP25000	 $                  191.75	 $                  295.00
	HD-LAMP-TITAN	 $                  249.00	 $                  349.00
	AIRO-LAMPPROHO	 $                    90.70	 $                  139.00
	 	 	 
	Filter
    Only Kit Part #	 	 
	HD-FILTER1200	 $                    19.46	 $                    29.95
	HD-FILTER1500	 $                    19.46	 $                    29.95
	HD-FILTER25000	 $                    25.97	 $                    39.95
	HD-FILTER-TITAN	 $                    32.95	 $                    49.95
	AIRO-FILTERPROHO	 $                    19.46	 $                    27.95

b. 
PCO Catalyst (i.e., the borosilicate glass tubes that are coated with the proprietary TiO2 solution and placed inside the Airocide
products’ reaction chambers) (“Catalyst”): $7.50 per pound until April 1, 2021, at which time it will increase
to $8.00 per pound.

 

Special
Terms with respect to the Catalyst: KES may also manufacture and produce the Catalyst under the terms of the License Agreement
with Akida and for the KES Products herein.

 

    	 	2	 

     

    

 

Exhibit
B

Bill
of Materials and Manufacturing Costs

 

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]